Cas:871940-23-7 3-Ethynyl-2-methoxyphenol manufacturer & supplier

We serve Chemical Name:3-Ethynyl-2-methoxyphenol CAS:871940-23-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Ethynyl-2-methoxyphenol

Chemical Name:3-Ethynyl-2-methoxyphenol
CAS.NO:871940-23-7
Synonyms:5-Ethynyl-2-methoxy-Phenol;2-(3-hydroxy-4-methoxyphenyl)ethyne;3-ETHYNYL-2-METHOXY-PHENOL
Molecular Formula:C9H8O2
Molecular Weight:148.15900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:29.46000
Exact Mass:148.05200
LogP:1.38210

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-Ethynyl-2-methoxy-Phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-ETHYNYL-2-METHOXY-PHENOL physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(3-hydroxy-4-methoxyphenyl)ethyne Use and application,5-Ethynyl-2-methoxy-Phenol technical grade,usp/ep/jp grade.


Related News: After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing. 3-Ethynyl-2-methoxyphenol manufacturer Chinese nationals coming from China and connecting through another foreign airport will be denied travel. Those with pre-clearance are exempted. 3-Ethynyl-2-methoxyphenol supplier After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing. 3-Ethynyl-2-methoxyphenol vendor The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 3-Ethynyl-2-methoxyphenol factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.